Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study
Crossref DOI link: https://doi.org/10.1007/s00535-015-1120-x
Published Online: 2015-09-25
Published Print: 2016-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hayashi, Norio
Nakamuta, Makoto
Takehara, Tetsuo
Kumada, Hiromitsu
Takase, Akiko
Howe, Anita Yee Mei
Ludmerer, Steven W.
Mobashery, Niloufar
Funding for this research was provided by:
MSD K.K., a subsidiary of Merck & Co., Inc.
License valid from 2015-09-25